Antiplatelet Activity of Coumarins: In Vitro Assays on COX-1

Atherosclerotic cardiovascular disease is the leading cause of death in developed countries. Therefore, there is an increasing interest in developing new potent and safe antiplatelet agents. Coumarins are a family of polyphenolic compounds with several pharmacological activities, including platelet...

Full description

Bibliographic Details
Main Authors: Cristina Zaragozá, Francisco Zaragozá, Irene Gayo-Abeleira, Lucinda Villaescusa
Format: Article
Language:English
Published: MDPI AG 2021-05-01
Series:Molecules
Subjects:
Online Access:https://www.mdpi.com/1420-3049/26/10/3036
_version_ 1827692039912816640
author Cristina Zaragozá
Francisco Zaragozá
Irene Gayo-Abeleira
Lucinda Villaescusa
author_facet Cristina Zaragozá
Francisco Zaragozá
Irene Gayo-Abeleira
Lucinda Villaescusa
author_sort Cristina Zaragozá
collection DOAJ
description Atherosclerotic cardiovascular disease is the leading cause of death in developed countries. Therefore, there is an increasing interest in developing new potent and safe antiplatelet agents. Coumarins are a family of polyphenolic compounds with several pharmacological activities, including platelet aggregation inhibition. However, their antiplatelet mechanism of action needs to be further elucidated. The aim of this study is to provide insight into the biochemical mechanisms involved in this activity, as well as to establish a structure–activity relationship for these compounds. With this purpose, the antiplatelet aggregation activities of coumarin, esculetin and esculin were determined in vitro in human whole blood and platelet-rich plasma, to set the potential interference with the arachidonic acid cascade. Here, the platelet COX activity was evaluated from 0.75 mM to 6.5 mM concentration by measuring the levels of metabolites derived from its activity (MDA and TXB<sub>2</sub>), together with colorimetric assays performed with the pure recombinant enzyme. Our results evidenced that the coumarin aglycones present the greatest antiplatelet activity at 5 mM and 6.5 mM on aggregometry experiments and inhibiting MDA levels.
first_indexed 2024-03-10T11:14:51Z
format Article
id doaj.art-1a975e0a36cd4368a7bd28d130b5b574
institution Directory Open Access Journal
issn 1420-3049
language English
last_indexed 2024-03-10T11:14:51Z
publishDate 2021-05-01
publisher MDPI AG
record_format Article
series Molecules
spelling doaj.art-1a975e0a36cd4368a7bd28d130b5b5742023-11-21T20:27:54ZengMDPI AGMolecules1420-30492021-05-012610303610.3390/molecules26103036Antiplatelet Activity of Coumarins: In Vitro Assays on COX-1Cristina Zaragozá0Francisco Zaragozá1Irene Gayo-Abeleira2Lucinda Villaescusa3Pharmacology Unit, Biomedical Sciences Department, University of Alcalá, Alcalá de Henares, 28871 Madrid, SpainPharmacology Unit, Biomedical Sciences Department, University of Alcalá, Alcalá de Henares, 28871 Madrid, SpainPharmacology Unit, Biomedical Sciences Department, University of Alcalá, Alcalá de Henares, 28871 Madrid, SpainPharmacology Unit, Biomedical Sciences Department, University of Alcalá, Alcalá de Henares, 28871 Madrid, SpainAtherosclerotic cardiovascular disease is the leading cause of death in developed countries. Therefore, there is an increasing interest in developing new potent and safe antiplatelet agents. Coumarins are a family of polyphenolic compounds with several pharmacological activities, including platelet aggregation inhibition. However, their antiplatelet mechanism of action needs to be further elucidated. The aim of this study is to provide insight into the biochemical mechanisms involved in this activity, as well as to establish a structure–activity relationship for these compounds. With this purpose, the antiplatelet aggregation activities of coumarin, esculetin and esculin were determined in vitro in human whole blood and platelet-rich plasma, to set the potential interference with the arachidonic acid cascade. Here, the platelet COX activity was evaluated from 0.75 mM to 6.5 mM concentration by measuring the levels of metabolites derived from its activity (MDA and TXB<sub>2</sub>), together with colorimetric assays performed with the pure recombinant enzyme. Our results evidenced that the coumarin aglycones present the greatest antiplatelet activity at 5 mM and 6.5 mM on aggregometry experiments and inhibiting MDA levels.https://www.mdpi.com/1420-3049/26/10/3036coumarinesculinesculetinantiplatelet activityimpedance aggregometryCOX
spellingShingle Cristina Zaragozá
Francisco Zaragozá
Irene Gayo-Abeleira
Lucinda Villaescusa
Antiplatelet Activity of Coumarins: In Vitro Assays on COX-1
Molecules
coumarin
esculin
esculetin
antiplatelet activity
impedance aggregometry
COX
title Antiplatelet Activity of Coumarins: In Vitro Assays on COX-1
title_full Antiplatelet Activity of Coumarins: In Vitro Assays on COX-1
title_fullStr Antiplatelet Activity of Coumarins: In Vitro Assays on COX-1
title_full_unstemmed Antiplatelet Activity of Coumarins: In Vitro Assays on COX-1
title_short Antiplatelet Activity of Coumarins: In Vitro Assays on COX-1
title_sort antiplatelet activity of coumarins in vitro assays on cox 1
topic coumarin
esculin
esculetin
antiplatelet activity
impedance aggregometry
COX
url https://www.mdpi.com/1420-3049/26/10/3036
work_keys_str_mv AT cristinazaragoza antiplateletactivityofcoumarinsinvitroassaysoncox1
AT franciscozaragoza antiplateletactivityofcoumarinsinvitroassaysoncox1
AT irenegayoabeleira antiplateletactivityofcoumarinsinvitroassaysoncox1
AT lucindavillaescusa antiplateletactivityofcoumarinsinvitroassaysoncox1